John van Duzer

Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2

Ronald E. Esser, Carol Berry, Zhengming Du et al. · British Journal of Pharmacology · 2005 · 123 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Discovery of Potent Poly(ADP-ribose) Polymerase-1 Inhibitors from the Modification of Indeno[1,2-<i>c</i>]isoquinolinone

Prakash G. Jagtap, Erkan Baloglu, Garry J. Southan et al. · Journal of Medicinal Chemistry · 2005 · 80 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +15

Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe et al. · Clinical Pharmacology in Drug Development · 2019 · 71 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant <i>Staphylococcus aureus</i>

Christopher K. Murphy, Steve Mullin, Marcia S. Osburne et al. · Antimicrobial Agents and Chemotherapy · 2006 · 40 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Rubén Niesvizky, Paul G. Richardson, Nashat Gabrail et al. · Blood · 2015 · 21 citations

Medicine, Oncology, Pharmacology +17